Dyax Corporation (DYAX)

Oncology Corporate Profile

Stock Performance


HQ Location

55 Network Drive
Burlington, MA 1803

Company Description

Dyax's mission is to discover, develop, and commercialize innovative biopharmaceuticals for unmet medical needs, while delivering outstanding value to patients and stockholders. Dyax's therapeutic product candidates include fully human monoclonal antibodies as well as small proteins and peptides. Dyax is particularly focused on medical advances in the areas of oncology and inflammation.

Website: http://www.dyax.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
DX-2240anti-Tie-1 monoclonal antibody (humanized)Various cancer typesPreclinicalSanofi
DX-2400anti-MMP-14 antibodyVarious cancer typesPreclinical

View additional information on product candidates here »

Source: http://www.dyax.com

Recent News Headlines

Drug Giant Shire Snaps Up Biotech Dyax for $5.9 Billion

11/3/2015 06:10 pm

(TheStreet) Nov 2, 2015 - The Dublin-based pharmaceutical will use the deal to bolster its rare disease drug portfolio, and says it can still afford to bid on larger target Baxalta.

GW Pharma's Cannabis Drug Fails in Cancer Pain Study, Shares Fall

1/8/2015 07:00 am

(Reuters) Jan 8, 2015 - An experimental cannabis drug failed to alleviate pain in cancer patients as hoped in a clinical study, sending shares in its British maker GW Pharmaceuticals as much as 21 percent lower on Thursday.

Dyax Corp. to Host Second Quarter 2012 Earnings Call and Webcast

6/28/2012 12:00 pm

[Business Wire] - Dyax Corp. will host a webcast and conference call, including an open question and answer session, Thursday, July 19, 2012. During the call, management will discuss t

Dyax Reports Results of Interim Analysis of Phase 2 Trial of Ecallantide for Acute Treatment of ACE Inhibitor-Induced Angioedema

6/14/2012 08:00 pm

[Business Wire] - Dyax Corp. announced today the decision to discontinue the Company’s Phase 2 trial investigating ecallantide in the acute treatment of angiotensin converting enzyme inhibitor-induced angioedema based upon the results of an interim analysis.

Dyax Announces Partnership with taiba for Distribution of Kalbitor® (ecallantide) in the Middle East

6/5/2012 12:00 pm

[Business Wire] - Dyax Corp. has granted exclusive distribution rights to taiba ME for the use of Kalbitor in the treatment of hereditary angioedema within the Middle East, including Saudi Arabia, United Arab Emirates, Oman, Bahrain, Qatar, Kuwait, Libya and Iran.

Dyax Announces Extension of Partnership with Bayer for Access to Dyax’s Fully-Human Antibody Phage Display Library

5/30/2012 12:00 pm

[Business Wire] - Dyax Corp. announced today, based on successful antibody discovery work during a research evaluation period, Bayer Pharma AG has executed a license to Dyax’s

Dyax Corp. to Participate in the Jefferies 2012 Global Healthcare Conference

5/29/2012 11:01 am

[Business Wire] - Dyax Corp. announced today that executive management will participate in the Jefferies 2012 Global Healthcare Conference, being held June 4-7, 2012 at the Grand Hyatt Hotel in New York City.

Dyax Launches HAE Diagnostic Testing Refund Program to Encourage Proper Diagnosis and Disease Management

5/24/2012 02:04 pm

[Business Wire] - Dyax Corp. the manufacturer of KALBITOR® for the treatment of acute attacks of hereditary angioedema in patients 16 years of age and older, has announced the launch of its HAE diagnostic testing refund program.

Dyax Corp. Reaffirms Commitment to Supporting Patients with Hereditary Angioedema on Inaugural HAE Day

5/16/2012 12:00 pm

[Business Wire] - As awareness activities take place today across the globe in recognition of Hereditary Angioedema Day –– Dyax Corp. has announced a donation of $25,000 to the United States Hereditary Angioedema Association – the largest HAE patient group in the world.

Dyax Corp. Launches Hereditary Angioedema (HAE) Attack Trackerâ„¢, a Free iPhone Application for HAE Patients

5/11/2012 11:01 am

[Business Wire] - Dyax Corp. today announced the launch of a free smartphone application for the iPhone – HAE Attack Tracker™. This application allows HAE patients to keep detailed re